Settipane Russell A, Bukstein Don A
Allergy Asthma Proc. 2022 Jul 1;43(4):350-355. doi: 10.2500/aap.2022.43.220017.
Clinical decision-making in allergic rhinoconjunctivitis management involves a significant degree of complexity given the number of pharmaceutical agents; the option for allergen immunotherapy (AIT); and the risk for disease advancement, including the development of asthma as well as new environmental allergic sensitivities. Given the complex array of treatment options that are currently available, there is an opportunity to use a shared decision-making (SDM) approach with associated aids and tools that facilitate the interactive participation of practitioners and patients in the SDM process. This article reviews the general constructs of SDM, the unmet need for SDM aids, the collection of patient preference data for allergic rhinoconjunctivitis, the utility of SDM aids which have been specifically created for AIT, and outlines actionable steps to implement AIT SDM in clinical practice.
在变应性鼻结膜炎的管理中，临床决策具有相当程度的复杂性，这是由于可用药物的数量众多、存在变应原免疫疗法（AIT）这一选择以及疾病进展的风险，包括哮喘的发生以及新的环境过敏敏感性。鉴于目前可用的治疗选择种类繁多，有机会采用共享决策（SDM）方法以及相关辅助工具，以促进从业者和患者在SDM过程中的互动参与。本文回顾了SDM的一般概念、对SDM辅助工具未满足的需求、变应性鼻结膜炎患者偏好数据的收集、专门为AIT创建的SDM辅助工具的效用，并概述了在临床实践中实施AIT SDM的可操作步骤。
